Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
THURSDAY, July 20, 2023 (HealthDay News) -- For patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival, according to a study published in the July 1 issue of The Lancet.
Arvind Dasari, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted an international, randomized, double-blind phase 3 study at 124 hospitals and cancer centers across 14 countries. Patients aged 18 years or older with histologically or cytologically documented metastatic colorectal adenocarcinoma who had received all current standard approved cytotoxic and targeted therapies and progressed on or were intolerant to trifluridine-tipiracil or regorafenib, or both, were included. A total of 691 patients were randomly assigned (2:1) to receive fruquintinib (5 mg capsule) or matched placebo orally once daily on days 1 to 21 followed by an off-week in 28-day cycles, plus best supportive care (461 and 230 patients, respectively).
The researchers found that median overall survival was 7.4 and 4.8 months in the fruquintinib and placebo groups, respectively (hazard ratio, 0.66). Grade 3 or worse adverse events occurred in 63 and 50 percent of patients receiving fruquintinib and placebo, respectively; the most common grade 3 or worse adverse events included hypertension, asthenia, and hand-foot syndrome in the fruquintinib group (14, 8, and 6 percent, respectively).
"The significant and clinically meaningful benefit with fruquintinib, the true extent of which will be more clear following analyses of the quality of life assessments, was coupled with a favorable safety profile," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including HUTCHMED, which manufactures fruquintinib and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Success of Enuresis Alarm Can Be ID’d After Two Weeks of Therapy
WEDNESDAY, Feb. 1, 2023 (HealthDay News) -- Children with a likelihood of...
Men Who Have Sex With Men Acting to Prevent Monkeypox Transmission
MONDAY, Aug. 29, 2022 (HealthDay News) -- Gay, bisexual, and other men who...
Pfizer planifica cobrar más de 100 dólares por dosis de la vacuna contra la COVID en 2023
LUNES, 24 de octubre de 2022 (HealthDay News) -- Algunos estadounidenses podrían...
Sleep a Key Defense for Black Americans at Genetic Risk for Alzheimer’s
THURSDAY, July 6, 2023 (HealthDay News) -- A lot of experts advise getting a...